Expression of CD2 in acute promyelocytic leukemia
correlates with short form of PML-RARalpha transcripts and poorer prognosis.
in correlation with all clinical data, confirmed a persistent disease state of acute promyelocytic leukemia
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
Coverage of the Acute Promyelocytic Leukemia
pipeline on the basis of route of administration and molecule type.
Extramedullary involvement at relapse in acute promyelocytic leukemia
patients treated or not with ATRA: A report by the GIMEMA Group.
Acute promyelocytic leukemia
(APL), a M3 type of AML based on French-American-British (FAB) classification, is uniquely sensitive to undergo terminal differentiation by differentiation-inducing agents, such as retinoids (i.
TRISENOX is indicated for the induction of remission and consolidation in patients with acute promyelocytic leukemia
(APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Tretinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia
(APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t (15;17) translocation and/or the presence of the PML/RARalpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated.
The company has four drug programs in clinical development: Tamibarotene, INNO-406, INNO-206, and INNO-305, for the treatment of acute promyelocytic leukemia
, chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively.
CTI)(Nasdaq: CTIC; Nuovo Mercato) announced today that a phase III study of TRISENOX consolidation treatment in patients with newly diagnosed acute promyelocytic leukemia
(APL) completed enrollment with approximately 500 patients.
CytRx is currently conducting a Phase 2b global clinical trial with tamibarotene as a first-line treatment for non-small-cell lung cancer (NSCLC) and a Phase 2 clinical trial with tamibarotene as a treatment for acute promyelocytic leukemia
Having been healthy all her life, in 2004 Christine was diagnosed with Acute Promyelocytic Leukemia
(APL), a rare type of leukemia.
Nippon Shinyaku) has launched TRISENOX(R) (arsenic trioxide) in Japan after receiving pricing approval from the Japanese Ministry of Health to market the drug for patients with relapsed or refractory acute promyelocytic leukemia
CytRx also is conducting a Phase 2 clinical trial with tamibarotene as a treatment for acute promyelocytic leukemia
CALGB and NCI Report Improved Survival in Newly Diagnosed Adult Patients with Acute Promyelocytic Leukemia
(APL) in Study Using TRISENOX --